WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s...
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia...
WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared...
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track...
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prelude Therapeutics Incorporated ("Prelude" or the "Company") (NASDAQ: PRLD). Such investors...
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the...
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs ...